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Genetic predisposition to cancer
A B S T R A C T
Objectives: Although the primary cause of lung cancer is smoking, a considerable proportion of all lung cancers
occur in never smokers. Gender influences the risk and characteristics of lung cancer and women are over-
represented among never smokers with the disease. Young age at onset and lack of established environmental
risk factors suggest genetic predisposition. In this study, we used population-based sampling of young patients to
discover candidate predisposition variants for lung adenocarcinoma in never-smoking women.
Materials and methods: We employed archival normal tissue material from 21 never-smoker women who had
been diagnosed with lung adenocarcinoma before the age of 45, and exome sequenced their germline DNA.
Results and conclusion: Potentially pathogenic variants were found in eight Cancer Gene Census germline genes:
BRCA1, BRCA2, ERCC4, EXT1, HNF1 A, PTCH1, SMARCB1 and TP53. The variants in TP53, BRCA1, and BRCA2
are likely to have contributed to the early onset lung cancer in the respective patients (3/21 or 14%). This
supports the notion that lung adenocarcinoma can be a component of certain cancer predisposition syndromes.
Fifteen genes displayed potentially pathogenic mutations in at least two patients: ABCC10, ATP7B, CACNA1S,
CFTR, CLIP4, COL6A1, COL6A6, GCN1, GJB6, RYR1, SCN7A, SEC24A, SP100, TTN and USH2A. Four patients
showed a mutation in COL6A1, three in CLIP4 and two in the rest of the genes. Some of these candidate genes
may explain a subset of female lung adenocarcinoma.
1. Introduction
Lung cancer is the most common cancer in the world and the
leading cause of cancer death [1]. It is highly fatal, with an overall
mortality to incidence ratio of 0.87. The primary risk factor for lung
cancer is cigarette smoke. Other established non-inherited risk factors
include ionizing radiation, asbestos, different kinds of occupational
exposures, air pollution and pulmonary diseases such as tuberculosis
and chronic obstructive pulmonary disease [2]. Lung cancer and pul-
monary fibrosis are driven by similar biological pathways [3], and a
recent study found an eightfold higher incidence ratio of lung cancer
among sufferers of idiopathic pulmonary fibrosis (IPF) when compared
to the general population [4]. A family history of lung cancer has been
estimated to double the risk of developing the disease [5,6], and the
heritability estimate based on the largest twin cohort to date (Nordic
Twin Study on Cancer) is 0.38 [7]. A number of susceptibility loci and
genes have been identified including 5p15 [8,9], 6p2 [10,11], 15q25.1
[10,11], EGFR [12–14], HER2 [15], BRCA [16], BAP1 [17], and PARK2
[18]. Also, germline TP53 and DICER1 mutations causing Li-Fraumeni
and DICER1 syndromes, respectively, are linked to an increased risk of
lung cancer [19,20].
The two main histological subtypes of lung cancer are small cell
lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC
originates from neuroendocrine-cell precursors, while NSCLC originates
from bronchial epithelial-cell precursors and can be further divided into
three types: squamous cell-, adeno- and large cell carcinoma. All major
histological subtypes of lung cancer are associated with smoking.
Epidemiological, pathological, and molecular evidence suggest that
lung cancer in never smokers should be treated as a distinct disease
entity [21]. Women are more likely to suffer from non-smoking-asso-
ciated lung cancer than men, reflecting sex-based differences in ex-
posure to risk factors and possibly also susceptibility [22]. A woman
with an affected parent has a higher risk than a man of developing lung
cancer, and the molecular profile and prognosis of the disease in
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women differs from that in men [23]. A key driver of lung adeno-
carcinoma tumorigenesis especially in never-smoker women is somatic
mutation of EGFR [24,25].
Here, we studied germline predisposition to lung adenocarcinoma
(LUAD) in never-smoking women, first identifying the youngest pa-
tients within the population-based Finnish Cancer Registry (FCR) da-
tabase. Young age at onset is a hallmark of hereditary susceptibility to
many common cancers. Normal tissue archival samples from never-
smoking female patients under 45 years of age were systematically
collected as guided by the database. The FCR harbors data on all cancer
cases diagnosed in Finland since 1953, totaling over one million cases.
2. Materials and methods
2.1. Ethics statement
This study was approved by the National Supervisory Authority for
Welfare and Health (Valvira; 1423/06.01.03.01/2012), National
Institute for Health and Welfare (THL; 151/5.05.00/2017), and the
ethics committee of the Hospital District of Helsinki and Uusimaa (HUS;
408/13/03/03/09).
2.2. Patients and samples
We included female never smokers listed in the FCR and diagnosed
with LUAD between 1953 and 2013, and before the age of 45. Smoking
histories were collected from patient records, and if there was no
mention of smoking habits the patient was excluded from the study.
Since the establishment of the FCR, altogether 105 women had been
diagnosed with LUAD before the age of 45. Of these 49 were current or
former smokers, 26 had no mention of smoking history or patient re-
cords were no longer available, and 30 were never smokers. Sufficient
quality normal tissue formalin-fixed, paraffin-embedded (FFPE) sam-
ples were available for 21 of the 30 never-smoking patients. Median age
at diagnosis was 39 for the exome sequenced samples (range 20–44).
We identified the first and second degree relatives of these patients
from the Population Information System, and checked their cancer
histories from the FCR. Family history of cancer as well as relevant
clinical information on the 21 patients that underwent exome analysis
are listed in Table 1. For 12 of the patients we collected tumor tissue
blocks in addition to the normal tissue blocks for loss of heterozygosity
(LOH) analysis.
In addition, we collected normal tissue FFPE blocks from six cancer
affected family members of LUAD11 (Fig. 1A), the parents of LUAD14,
and the son of LUAD24 (Fig. 1B) who suffered from IPF.
2.3. Exome sequencing
We extracted genomic DNA from normal tissue archival tissue
samples with the conventional phenol-chloroform method and prepared
the DNA samples for exome sequencing with the KAPA Hyper Prep Kit
(Kapa Biosystems Inc., Wilmington, MA) and SeqCap EZ System (Roche
Nimblegen Inc., Madison, WI). The sources of the FFPE tissue and
Table 1
Age at diagnosis and family history of malignancy or lung disease of the lung adenocarcinoma patients.
Patient Age at diagnosis Family cancer/lung disease history
LuAd1 38 Multiple myeloma (maternal grandmother, 87); breast carcinoma NOS (maternal aunt, 33); bladder adenocarcinoma (maternal uncle, 69)
LuAd3 36 Prostate adenocarcinoma (father, 75; paternal grandfather, 59); lymphocytic leukemia NOS (paternal cousin, 5)
LuAd5 33 Colorectal adenocarcinoma and prostate adenocarcinoma (maternal grandfather, 78 and 86)
LuAd6 38 Hodgkin lymphoma NOS (brother, 26)
LuAd7 31 Brain carcinoma NOS (paternal grandmother, 77); prostate adenocarcinoma (paternal grandfather, 88; paternal uncle, 68; paternal uncle, 68);
cervical squamous cell carcinoma (paternal cousin, 40); nasal rhabdomyosarcoma (paternal cousin, 0); ductal breast cancer (maternal cousin, 39)
LuAd8 20 Breast carcinoma NOS and uterine adenocarcinoma NOS (mother, 57 and 77); breast carcinoma NOS (maternal aunt, 52); prostate adenocarcinoma
(maternal grandfather, 79)
LuAd10 29 Lung squamous cell carcinoma (father, 59)
LuAd11 35 Mucinous gastric adenocarcinoma (father, 62); prostate adenocarcinoma (paternal uncle, 67; paternal uncle, 69); oral squamous cell carcinoma
(paternal aunt, 59 and 67); diffuse large B-cell lymphoma (paternal uncle, 83); ductal breast carcinoma (paternal cousin, 47)
LuAd13 29 Gastric adenocarcinoma (maternal grandmother, 67; father, 81); ductal breast carcinoma (mother, 70); cervical squamous cell carcinoma (daughter,
21); renal adenocarcinoma (paternal cousin, 66); diffuse large B-cell lymphoma (paternal cousin, 66)
LuAd14 21 Pancreatic carcinoma (maternal grandfather, 82); lymphocyte-rich classical Hodgkin lymphoma (father, 24); lung cancer NOS (paternal aunt, 51);
urothelial carcinoma (paternal grandfather, 68); prostate adenocarcinoma (paternal grandfather, 68)
LuAd15 41 N/A
LuAd18 40 Breast carcinoma NOS (maternal aunt, 34)
LuAd19 39 Brain cancer NOS (paternal uncle, 47); Ewing's sarcoma (paternal cousin, 29)
LuAd20 41 Ductal breast carcinoma (paternal aunt, 61), colorectal adenocarcinoma (maternal grandmother, 87)
LuAd21 41 Ductal breast carcinoma (sister, 53), colorectal adenocarcinoma (maternal grandmother, 74), prostate adenocarcinoma (paternal grandfather, 73)
LuAd23 42 Urothelial carcinoma (maternal grandfather, 79)
LuAd24 44 Colorectal adenocarcinoma (half brother, 57); lung adenocarcinoma (brother, 43); usual interstitial pneumonia (son, XX)
LuAd26 42 Prostate adenocarcinoma (maternal half uncle, 62)
LuAd27 44 Lobular breast cancer (sister, 42); renal adenocarcinoma (father, 62); ductal breast cancer (paternal cousin, 48)
LuAd29 42 N/A
LuAd31 43 N/A
Fig. 1. A. Pedigree of LUAD11. B. Pedigree of LUAD24. Pedigrees have been
slightly modified to prevent identification of individuals. Index cases are
marked with arrows. Numbers under the individuals stand for the age at cancer
diagnosis.
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subsequent DNA samples are listed in Table 2. We used 300–1000 ng of
DNA sheared to an average size of 200–300 bp with the Covaris S220
Focused-ultrasonicator (Covaris Inc., Woburn, MA). For target enrich-
ment, we used the 96 Mb SeqCap EZ Exome+UTR kit (Roche Nim-
blegen Inc.). Paired-end sequencing was carried out with Illumina
HiSeq 2000 or 4000 (Illumina, San Diego, CA) at Karolinska High
Throughput Center.
DNA from 21 female patients and the IPF afflicted son of LUAD24
was exome sequenced successfully with an average coverage of targeted
areas being 48 reads across all samples, and 91% of targeted areas being
covered by more than six reads.
2.4. Data analysis
The quality of raw sequencing data was examined using FastQC
version 0.10.0 (http://www.bioinformatics.bbsrc.ac.uk/projects/
fastqc/) and QualiMap version 2.1 (http://qualimap.bioinfo.cipf.es/).
3′ ends of reads with high adapter similarity were removed with Trim
Galore! version 0.3.07 (http://www.bioinformatics.babraham.ac.uk/
projects/trim_galore/) and trimmed reads were mapped to 1000 gen-
omes Phase 2 reference genome (GRCh37 / hg19) with Burrows-
Wheeler Aligner (BWA)–MEM version 0.7.12 [26]. Overlapping read
pairs were clipped using BamUtil version 1.0.13 (http://genome.sph.
umich.edu/wiki/BamUtil#Releases) ClipOverlap. Duplicate reads were
removed using Samtools version 1.0 (http://www.htslib.org/) rmdup
on both paired-end and single-end reads. Aligned reads were locally
realigned using the GATK version 3.5 [27] IndelRealigner and base
scores were recalculated with GATK BaseRecalibrator. After realign-
ment the final SNV and indel calls were made with the GATK Haplo-
typeCaller using a variant quality threshold of 1.0.
Annotation, comparative variant analysis, controlling and variant
visualization were performed with BasePlayer (https://doi.org/10.
1101/126482). Gene annotation was based on Ensembl GRCh37 re-
lease 84. Minimum variant quality score was set at 20, minimum cov-
erage at six reads, and minimum allelic fraction at 30%. The data was
filtered against the variant MAFs of gnomAD, available at the Genome
Aggregation Database [28]. We required passed variants to have a MAF
of< 0.001 in the gnomAD Finnish subset, which is made up of 12,897
individuals. Three patients (LUAD15, LUAD29 and LUAD31) were of
Southeast Asian ancestry, however. For these patients gnomAD
populations East Asian (9435 individuals) and South Asian (15,391
individuals) were used, with a MAF threshold of< 0.001. Effects of
missense variants were predicted with M-CAP [29]. Missense variants
outside the range of M-CAP (mainly variants in other than the canonical
transcript) as well as in-frame deletions and insertions were predicted
by Provean [30]. Variants were required to get a deleterious prediction
using the algorithms’ default threshold values in order to pass filtering.
2.5. Sanger sequencing and LOH analysis
The variants were verified by Sanger sequencing of DNA extracted
from FFPE blocks with the GeneRead DNA FFPE Kit (Qiagen). Primers
were designed with Primer3web version 4.0.0 [31] and capillary se-
quencing was performed at the Institute for Molecular Medicine Finland
(FIMM) using the BigDye v.3.1 sequencing reaction and ABI3730xl
DNA Analyzer electrophoresis (Applied Biosystems, Foster City, CA).
Sequences were analyzed manually using FinchTV 1.5. LOH was de-
termined by comparing peaks between normal and tumor (> 50%
tumor tissue) samples when tumor tissue was available (12 cases). Each
reaction was performed in triplicate to ensure consistency of the ob-
servations and exclude mono-allelic amplification. Normal tissue DNA
from a total of eight relatives of LUAD11 and LUAD14 was also se-
quenced to see whether candidate variants in the patients segregated
with malignancy.
3. Results and discussion
More than 100 cancer predisposition genes have been identified to
date. A recent pan-cancer study that included more than 10,000 cases
across 33 different cancers discovered plausible susceptibility variants
in 8% of all patients [32]. However, the genetic architecture of lung
cancer susceptibility is not well known. In the previously mentioned
study [32], probable predisposing variants were found in more than 6%
of LUAD. Another study, that analyzed the amount of rare germline
truncating variants in cancer predisposition genes across 12 cancer
types, found a similar rate (7%) for LUAD [33]. Here we performed a
population based search through the FCR to identify young female
patients diagnosed with the malignancy, as early age at onset is a
hallmark of inherited cancer susceptibility. Family history was also
looked into, but this was not a criteria for inclusion or exclusion.
We looked into genes listed in the Cancer Gene Census (CGC),
available in the Catalogue of Somatic Mutations in Cancer (COSMIC)
database [34], to see whether the patients could be suffering from
known cancer predisposition syndromes. We observed eight potentially
pathogenic heterozygous mutations (MAF < 0.001) in eight CGC
germline genes (Table 3). The variants in TP53, BRCA1, and BRCA2, are
in light of current knowledge likely to have contributed to the early-
onset lung cancer in our patients. The TP53-nonsense mutation
p.Gln52Ter was not found in any controls and has, to our knowledge,
not previously been reported as a germline variant. Due to its trun-
cating nature, it is likely to have an effect on the protein function.
Constitutional mutations in TP53 predispose to multiple different can-
cers in the carriers. The gene is mutated in approximately 70% of pa-
tients with Li-Fraumeni syndrome (LFS) and 40% of patients with Li-
Fraumeni-Like syndrome (LFL) [35]. These conditions are characterized
by predisposition to a wide spectrum of neoplasia, including soft-tissue
sarcoma, osteosarcoma, leukemia, breast cancer, brain tumors, and
adrenocortical carcinoma, often at early age at onset. Although lung
cancer is not a classic LFS spectrum cancer, it has been linked to LFS
[19,36]. Preliminary data from the LIFESCREEN randomized clinical
trial suggest that LUAD is indeed part of the spectrum, being the most
frequent tumor in the LFS cohort under study [37]. As a somatic mu-
tation, the observed variant has been described 13 times in COSMIC.
The patient carrying it was diagnosed at the age of 22. Both parents
carried wild type alleles, indicating a de novo background. This finding
further diminishes the possibility that the variant is a neutral change.
Table 2
Source of non-malignant DNA sample.
Patient Source of DNA sample













LuAd20 Lung with lymph node
LuAd21 Posterior mediastinal lymph node
LuAd23 Duodenum
LuAd24 Lung





a variants validated by Sanger sequencing of DNA sample from breast.
b variants validated by Sanger sequencing of DNA sample from skin.
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The BRCA1 variant p.Cys47Arg was found in a patient diagnosed
with LUAD at the age of 35. The variant could not be found among the
controls, nor has it been reported as a germline variant or to be so-
matically mutated. Residue 47 is a zinc coordinating residue located in
the conserved RING motif of BRCA1. It is critical for the binding of
BARD1. Functional studies have shown that another variant of this
residue, Cys47Gly, is defective in homology-directed recombination
(HDR) [38]. BARD1 binding and HDR are critical for the tumor sup-
pressive function of BRCA1. Furthermore, the Cys47Gly variant has
been found to cause centrosome duplication [39]. BRCA1 is a well-es-
tablished breast and ovarian cancer susceptibility gene. Considering the
rarity of the discovered variant and its critical location, it is plausible
that it was involved in the carcinogenesis of LUAD in the patient in
question. The variant was inherited from the father who was diagnosed
with gastric cancer at the age of 62. A number of studies have found an
increased risk of gastric cancer in BRCA1 mutation carriers [40–42]. Of
the other cancer afflicted family members of whom we were able to
attain tissue material, the variant was also found in an uncle with
lymphoma at the age of 83 as well as a female cousin with breast cancer
at the age of 47 (Fig. 1A).
A plausible susceptibility variant was also found in BRCA2:
p.Arg2784Trp. The mouse equivalent of this residue, p.Arg2705, forms
hydrogen bonds with the side chains of the residues p.Asn2702 (human
p.Asn2781) and p.Ser2728 (human p.Ser2807), as well as the p.Asp41
side chain of DSS1, and thus holds together three loops [43]. The
p.Arg2784Trp mutation in our patient may affect tertiary interactions
between DNA-binding folds as well as the interaction between BRCA2
and DSS1, which is required for the stability of BRCA2 [44]. The variant
also scored similar as known pathogenic BRCA2 variants in an HDR
assay [43]. The carrier was of Southeast Asian origin and diagnosed at
the age of 43. Rare variants in BRCA2 have been found to affect the risk
of lung squamous cell carcinoma in a genome-wide association study
[16]. In addition, a recent study on LUAD found a significant number of
germline ultra-rare possibly pathogenic variants in BRCA2 [45].
Altogether 15 genes harbored a rare (MAF < 0.001) potentially
pathogenic variant in at least two patients within the series. The 33
variants are listed in Table 4. None of the recurrently mutated genes
were among the CGC germline genes. The most frequently mutated
candidate gene in the sample set was COL6A1. Three patients harbored
one, and one patient harbored two heterozygous missense variants in
the gene. The protein product COL6A1 has three von Willebrand factor
type A (VWA) domains, and all the variants were located in these do-
mains. VWA domains are likely to mediate protein-protein interactions
by coordination of divalent cations [46]. Exon skipping, nonsense and
some missense mutations in COL6A1 cause Bethlem myopathy 1 [47],
and the gene has been found to be overexpressed in neoplastic lung
tissues [48]. The second most frequently mutated gene with a variant in
three patients was CLIP4. Little is known about the function of its
protein product.
SCN7A was heterozygously mutated in two patients, including
LUAD24, who shared the c.1133C > T variant with her son who suf-
fered from IPF. The family had a notable history of lung disease in
general (Fig. 1B). Other potentially pathogenic variants shared by
LUAD24 and her son are listed in Table 5. SCN7A is a sodium channel
which is altered by sodium concentrations instead of membrane de-
polarization. The channels contribute to sodium absorption by cells
when extracellular sodium levels are high, and channels in the cir-
cumventricular organs are also likely to be involved in the control of
water and salt uptake behavior and thus body fluid homeostasis. SCN7A
is expressed in specialized neurons, specialized ependymal and glial
cells, non-myelinating Schwann cells, and lung alveolar type II (AT2)
cells [49]. AT2 is the main cell type responsible for the secretion of
surfactant proteins SFTPC and SFTPA2. Interestingly, mutations in the
genes SFTPC and SFTPA2 have been found to cause familial interstitial
pneumonia [50], a hereditary form of IPF. The other variant,
c.1003T > C, was found in LUAD21. We did not have tumor tissue
from patient LUAD24, but Sanger sequencing of tumor-derived DNA
from LUAD21 showed a decrease in the WT allele signal.
The remaining 13 shared genes (Table 4) were heterozygously
mutated in two patients. CFTR is the most prominent candidate gene
with regards to known function. Homozygous or compound hetero-
zygous mutations in CFTR cause cystic fibrosis. A variant (c.1558G >
T) affecting the same nucleotide as one of the two variants found in this
study is listed as a cystic fibrosis causing mutation in the The Clinical
and Functional Translation of CFTR (CFTR2) database (http://cftr2.
org). The relationship between cystic fibrosis and lung cancer is un-
clear, but both frequent hypermethylation [51] and mutation [52] of
CFTR have been observed in NSCLCs. A recent study found lower ex-
pression of CFTR in tumors and showed that the expression levels
correlated with disease stage, lymph node metastasis, poor prognosis,
and progression-free survival [53]. Knockdown of CFTR enhanced the
malignant behavior of NSCLC, whereas its overexpression suppressed
cancer progression in vitro and in vivo. The two patients in this study
carrying CFTR variants were of Southeast Asian ancestry.
Somatic loss of heterozygosity was observed at 4/25 tested loci in
12 tumor samples. We analyzed the variants listed in Tables 3 and 4 in
the respective patients in the cases in which tumor tissue material was
available (LUAD3, LUAD5, LUAD10-11, LUAD13-15, LUAD18-21, and
LUAD26). The results of the LOH analysis are listed along with the
variants in Tables 3 and 4. A decrease of the wild type allele signal was
observed for SMARCB1 in LUAD3, and both SP100 and SCN7A in
LUAD21. SMARCB1 is part of the SWF/SNF complex and a tumor
suppressor gene, loss-of-function mutations in it cause rhabdoid pre-
disposition syndrome, while non-truncating splice-site and missense
mutations have been found to cause familial schwannomatosis. The
variant here has to our knowledge not previously been found in the
Table 3
Potentially pathogenic variants found in Cancer Gene Census germline genes.
Gene Variant locationa Base changeb Variant effect rs-code Population MAF gnomAD MAF Patient LOH
BRCA1 chr17:41258546 c.139A > G p.(Cys47Arg) N/A N/A N/A LuAd11 N/A
BRCA2 chr13:32944557 c.8350C > T p.(Arg2784Trp) rs80359075 5.80E-05* 1.22E-05 LuAd31 N/A
ERCC4 chr16:14031664 c.1853G > T p.(Arg618Leu) rs760922582 8.59E-04 1.29E-04 LuAd19 None
EXT1 chr8:119123269 c.17C > G p.(Arg6Pro) rs200815125 7.67E-05 4.38E-06 LuAd26 None
HNF1A chr12:121434127 c.1018C > G p.(Pro340Ala) rs746055869 4.27E-04 4.33E-04 LuAd24 N/A
PTCH1 chr9:98231178 c.2105 G > C p.(Pro702Arg) rs368362152 5.30E-05* 1.44E-05 LuAd31 N/A
SMARCB1 chr22:24134046 c.197C > T p.(Ser66Leu) N/A N/A N/A LuAd3 WT loss
TP53 chr17:7579533 c.154G > A p.(Gln52*) N/A N/A N/A LuAd14 None
Abbreviations: MAF, minor allele frequency; LOH, loss of heterozygosity; WT, wild type; mut, mutant.
Population MAF refers to the gnomAD Finnish population, except for patients LuAd15, LuAd29 and LuAd31 who are of Southeast Asian ancestry. For these gnomAD
populations East Asian (*) and South Asian (**) were used, depending on which one had the higher allele frequency.
a Genome assembly GRCh37.
b Position in longest translation (GRCh37 release 84).
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germline, but twice as a somatic mutation in colorectal cancer, one
being a de novo mutation in a lung metastasis [34]. Its role in the
carcinogenic process in our patient remains elusive, however.
During the review process of this manuscript, a study on the mu-
tational profile of 36 young LUAD patients was published [54]. Besides
characterizing unique somatic mutational features of this patient sub-
group, potential predisposing mutations were also identified. Such
variants were found in TP53 and BRCA2 supporting some of the find-
ings in our study, and showing the value of multiple independent efforts
to elucidate the molecular basis of this devastating disease.
4. Conclusions
This population-based study on a highly selected sample set, to-
gether with prior reports on germline variants in known cancer pre-
disposition genes in lung cancer, calls for a broadening of the cancer
spectrum of cancer syndromes caused by TP53, BRCA1, and BRCA2
mutations, and highlights genetic susceptibility as a relevant cause for
LUAD in young females. This study also provides a set of candidate
predisposition genes, some of which may explain a subset of female
LUAD, for validation in other similar materials. Symptoms of lung
Table 4
Genes mutated more than once within the patient series.
Gene Variant locationa Base changeb Variant effect rs-code Population MAF Patient LOH
COL6A1 chr21:47421948 c.2030G > A p.(Arg677His) rs373731596 N/A LuAd20 None
chr21:47423767 c.2927G > A p.(Arg976His) rs753485651 9.13E-05 LuAd20 None
chr21:47404364 c.409C> G p.(Leu137Val) rs139648899 6.71E-04 LuAd8 N/A
chr21:47404379 c.424G > C p.(Val142Leu) rs144282452 6.83E-04 LuAd21 None
chr21:47402620 c.170C > A p.(Ala57Asp) rs143502850 3.10E-04 LuAd10 None
CLIP4 chr2:29356586 c.433C > T p.(Arg145Trp) rs373336528 1.94E-04 LuAd23 N/A
chr2:29356586 c.433C > T p.(Arg145Trp) rs373336528 1.94E-04 LuAd13 Mut loss
chr2:29375679 c.1150T > G p.(Ser384Ala) N/A N/A LuAd31 N/A
ABCC10 chr6:43415549 c.3833T > C p.(Ile1278Thr) rs200393514 7.88E-04 LuAd18 None
chr6:43417692 c.4342C > T p.(Arg1448Trp) rs200628851 8.54E-04 LuAd11 None
ATP7B chr13:52536004 c.1915G > A p.(His639Tyr) rs200728096 N/A LuAd5 WT loss
chr13:52513231 c.3649_3654delGTTCTG p.(Val1217_Leu1218del) rs781266802 2.24E-04 LuAd19 None
CACNA1S chr1:201021734 c.3904G > A p.(Arg1302Trp) rs780390034 7.76E-05 LuAd20 None
chr1:201046075 c.1800A > T p.(Phe600Leu) N/A N/A LuAd10 None
CFTR chr7:117199683 c.1558G > A p.(Val520Ile) rs77646904 N/A LuAd31 N/A
chr7:117232086 c.1865G > A p.(Gly622Asp) rs121908759 4.87E-04* LuAd29 N/A
COL6A6 chr3:130368133 c.5460_5461insC p.(Lys1821Glnfs) rs761569826 6.11E-05* LuAd31 N/A
chr3:130284164 c.989_990delAG p.(Gln330Argfs) rs767662986 N/A LuAd26 None
GCN1 chr12:120580400 c.5740T > G p.(Asn1914His) rs746987106 8.97E-05 LuAd19 None
chr12:120572361 c.7178C > T p.(Arg2393His) rs200245091 2.33E-04 LuAd1 N/A
GJB6 chr13:20796839 c.781T > A p.(Ser261Cys) rs143962007 4.49E-05 LuAd6 N/A
chr13:20797241 c.379G > A p.(Arg127Trp) N/A N/A LuAd19 None
RYR1 chr19:39027398 c.11599C > T p.(Arg3867Cys) rs138593495 N/A LuAd26 None
chr19:38966047 c.4250C > T p.(Ala1417Val) rs779275405 9.03E-05 LuAd14 None
SCN7A chr2:167313537 c.1133C > T p.(Ser378Asn) rs775112434 N/A LuAd24 N/A
chr2:167318979 c.1003T > C p.(Asn335Asp) rs771820272 1.94E-04 LuAd21 WT loss
SEC24A chr5:134015331 c.1294A > G p.(Arg432Cys) rs757964453 N/A LuAd25 N/A
chr5:134032900 c.2071A > T p.(Leu691Phe) rs199840978 7.76E-04 LuAd13 None
SP100 chr2:231405625 c.2245A > T p.(Thr749Ser) rs550426045 6.83E-04** LuAd29 N/A
chr2:231333785 c.1319C > T p.(Thr440Ile) rs749074736 8.99E-05 LuAd21 WT loss
TTN chr2:179425967 c.84892G > A p.(Arg28298Trp) rs779581886 4.50E-05 LuAd8 N/A
chr2:179598232 c.15788A > T p.(Ile5263Asn) rs776892266 8.19E-04 LuAd6 N/A
USH2A chr1:215960068 c.10331C > T p.(Cys3444Tyr) N/A 5.80E-05* LuAd15 None
chr1:216373413 c.3367A > G p.(Tyr1123His) rs794729204 5.05E-04 LuAd10 None
Abbreviations: MAF, minor allele frequency; LOH, loss of heterozygosity; WT, wild type; mut, mutant.
Population MAF refers to the gnomAD Finnish population, except for patients LuAd15, LuAd29 and LuAd31 who are of Southeast Asian ancestry. For these gnomAD
populations East Asian (*) and South Asian (**) were used, depending on which one had the higher allele frequency.
a Genome assembly GRCh37.
b Position in longest translation (GRCh37 release 84).
Table 5
Variants shared between LuAd24 and IPF afflicted son.
Gene Variant locationa Base changeb Variant effect rs-code gnomAD Finnish MAF
ACTR2 chr2:65495807 c.1139G > A p.(Arg380Gln) rs757353258 1.94E-4
SCN7A chr2:167313537 c.1133C > T p.(Ser378Asn) rs775112434 N/A
RAET1L chr6:150342163 c.508delG p.(Glu170Lysfs) rs745880461 8.97E-5
PLEC chr8:144991271 c. 13129C > T p.(Ala4377Thr) rs201688261 1.56E-4
ZFAND4 chr10:46159086 c. 88G > A p.(Leu30Phe) rs147435712 6.99E-4
PDE6C chr10:95422371 c.2339_2344delTTGATT p.(Asp781_Phe782del) rs765688777 1.35E-4
GPHN chr14:66975273 c.28A > T p.(Asn10Tyr) rs121908539 N/A
HERC1 chr15:63926054 c.12686G > A p.(Ser4229Leu) rs199683306 3.11E-4
NKD1 chr16:50642262 c.250C > T p.(Arg84Trp) rs201400910 7.94E-5
FBXO39 chr17:6683762 c.576delG p.(Asn193Metfs) rs769388797 N/A
Abbreviations: MAF, minor allele frequency.
a Genome assembly GRCh37.
b Position in longest translation (GRCh37 release 84).
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cancer often appear only at an advanced stage, and most cases are di-
agnosed when treatment options are limited. Identifying individuals
with high genetic risk is important, since such knowledge provides
opportunities for early diagnosis and improved management, including
efforts towards cancer prevention in the at-risk relatives.
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